Glucotrack appointed Erik Emerson to the Acquiror Board, filling a newly created seat effective upon the Closing.
| IndividualErik Emerson | RoleDirector (appointed to Acquiror Board) | Type of ChangeAppointed | Effective DateEffective upon the Closing (appointment made July 9, 2026) | ReasonBoard expansion from five to six members; appointment to fill vacancy | Replacement InfoNot disclosed | Background Details55; 25-year biopharma veteran; prior CEO roles at Apimeds Pharmaceuticals US and Lokahi Therapeutics; CCO roles at Odyssey Neuropharma, Mezzion, Adhera; other executive and commercial roles including Gilead, Xoma, Symplmed (max 200 chars) | Board/Committee Role ChangesNot disclosed |
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.